Vinpocetine

What it is

Vinpocetine was developed in the late 1960s. Chemically it is an ethyl ester of apovincamine, derived from vincamine, an alkaloid of the lesser periwinkle Vinca minor. Under the name Cavinton from the Hungarian manufacturer Gedeon Richter, it has been used for more than five decades for impaired blood flow to the brain.

In Germany, medicines containing vinpocetine were on the market until 2006, but no longer since then. In the US and in online retail, by contrast, vinpocetine appears as a memory supplement, often also in nootropic blends and fat burners.

How it is supposed to work

The classic mechanism is the inhibition of phosphodiesterase 1. This enzyme breaks down the signaling molecules cAMP and cGMP, which among other things relax blood vessels. More cAMP and cGMP mean wider vessels and, so the idea goes, better blood flow to the brain. In addition, vinpocetine blocks voltage-gated sodium channels, which is supposed to protect nerve cells from overstimulation during oxygen deprivation.

A third pathway was described in 2010: vinpocetine directly inhibits the enzyme IKK and thus the inflammatory switch NF-κB, independently of phosphodiesterase. This comes from cell culture and a mouse model. In 60 stroke patients who received vinpocetine as an infusion, NF-κB activation was indeed dampened. Newer studies also show that vinpocetine enhances GABA-A receptors, which is being investigated in rare genetic epilepsies.

Oral absorption is weak. In humans only about 6.2 percent reaches the blood; with a meal, absorption increases by about 60 to 100 percent. Blood levels are thus far below those that are effective in animal studies.

A new lead: rare epilepsies

A surprising new field of research is genetic epilepsies in which GABA-A receptors work too weakly. Vinpocetine enhances these receptors in the laboratory. In a Danish observational series with 9 patients who received vinpocetine in addition to their therapy, one became seizure-free and two had 50 to 55 percent fewer seizures. This is an isolated finding without a control group, but it shows that the substance can do more pharmacologically than just influence blood flow.

What is in the capsules

Anyone who finds vinpocetine in online retail is usually buying US products. Their quality is a problem in itself. Of 23 US supplements with vinpocetine on the label, 17 contained the active substance in widely varying amounts; in 6 it was not detectable at all. In another analysis of 10 nootropic products, vinpocetine turned up without being listed on the label in every case.

What the studies show

Cochrane review on dementia

The Cochrane authors found 3 double-blind studies with a total of 583 people with dementia, all conducted before the 1990s. Vinpocetine performed better than placebo, but only a few patients were treated for 6 months or longer, and only one study ran for 1 year. The conclusion: inconclusive, not sufficient for clinical use.

CAVIN study in China

In an open-label, multicenter study, 610 patients with acute cerebral infarction received standard therapy, 469 of them additionally received vinpocetine as an infusion for 7 days. After 90 days, the memory test, neurological scale and everyday abilities were better in the vinpocetine group. There was no placebo.

Animal studies on pregnancy

The US National Toxicology Program (NTP) gave pregnant rats and rabbits vinpocetine during organ development. In the rats, more embryos were lost after implantation, and in all treated groups defects of the cardiac septum occurred more frequently, without the mothers appearing clearly ill. The NTP assessed this as clear evidence of developmental toxicity.

Healthy people and epilepsy patients

In a double-blind crossover study, 8 healthy adults and 8 people with focal epilepsy received single doses of vinpocetine or placebo. No cognitive benefits were seen. The authors suspect that blood levels in humans are too low.

Where the data stop

For the typical biohacking purpose, that is, more focus and better memory in healthy people, there is practically nothing reliable. A study with 12 healthy women found an improvement after 2 days in only one of several tests; the study with 8 healthy people found none at all. In Alzheimer’s disease, an open-label study with 15 patients over 1 year showed no effect.

The stroke data also have limits. The 2008 Cochrane review found only 2 small studies with 70 participants and could not draw any conclusion. The positive 2022 meta-analysis rests on few, partly small studies; a reduction in mortality has not been demonstrated. The most important newer studies gave vinpocetine as an infusion in hospital, which cannot be transferred to capsules. It is also open what amount would make sense at all: in the largest dementia study, the higher dose level did not perform better than the lower one, and in healthy people the achievable blood levels are far below those effective in animals.

Status, approval and legal

In Germany, vinpocetine is explicitly prescription-only; a finished medicinal product has no longer been on the market since 2006. It is not marketable as a food supplement; in the European rapid alert system RASFF it has been reported four times since 2021 as an unauthorized substance in food supplements. In other countries, such as China and Russia, it is considered a medicine. In the US, the FDA has provisionally not considered vinpocetine a permissible supplement ingredient since 2016, and the US Department of Defense lists it on its prohibited list for dietary supplements. Vinpocetine is not on the WADA Prohibited List 2026.

Safety

In the studies, vinpocetine was well tolerated in the short term. Facial flushing, headache, sleep disturbances, nausea and dizziness have been described. The greatest risk concerns pregnancy: in 2019 the FDA warned that vinpocetine could cause miscarriage or harm the development of the child. This is based on studies by the US National Toxicology Program in which pregnant rats lost more embryos and the offspring more frequently had cardiac septal defects; in 2026 experiments on human stem cell models confirmed the disruption of early development. Anyone who is or could become pregnant should therefore avoid vinpocetine. Caution applies with blood thinners, even though a study with 18 men on warfarin found only minimal interference. Then there is product quality: in 6 of 23 US supplements, no vinpocetine at all was detectable.

Sources

• Szatmari and Whitehouse, Cochrane Database of Systematic Reviews 2003 – vinpocetine for cognitive impairment and dementia
• Bereczki and Fekete, Cochrane Database of Systematic Reviews 2008 – vinpocetine for acute ischemic stroke
• Panda et al., Neurocritical Care 2022 – meta-analysis on acute ischemic stroke
• Zhang et al., Clinical Drug Investigation 2016 – CAVIN study
• Hindmarch et al., International Clinical Psychopharmacology 1991 – RCT with 203 patients
• Meador et al., Epilepsy and Behavior 2021 – cognition in healthy people and epilepsy
• Jeon et al., PNAS 2010 – inhibition of NF-κB via IKK
• National Toxicology Program 2020 – prenatal developmental toxicity in rats and rabbits
• FDA – Vinpocetine in Dietary Supplements
• Avula et al., Drug Testing and Analysis 2016 – vinpocetine content in US supplements